- Home
- HCA vs MRNA Comparison
HCA vs MRNA Comparison
Compare HCA & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HCA | MRNA |
|---|---|---|
| Founded | 1968 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.7B | 91.2B |
| IPO Year | 2009 | 2018 |
Fundamental Metrics
Financial Performance| Metric | HCA | MRNA |
|---|---|---|
| Price | $496.55 | $255.93 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 26 | 23 |
| Target Price | ★ $475.45 | $138.37 |
| AVG Volume (30 Days) | 1.4M | ★ 16.5M |
| Earning Date | 10-27-2026 | 11-06-2026 |
| Dividend Yield | ★ 0.61% | N/A |
| EPS Growth | ★ 28.77 | 21.77 |
| EPS | ★ 22.05 | N/A |
| Revenue | ★ $75,600,000,000.00 | $19,263,000,000.00 |
| Revenue This Year | $4.71 | $8.13 |
| Revenue Next Year | $3.16 | $16.26 |
| P/E Ratio | $23.16 | ★ N/A |
| Revenue Growth | ★ 7.08 | 4.29 |
| 52 Week Low | $353.99 | $22.28 |
| 52 Week High | $556.52 | $258.72 |
Technical Indicators
Market Signals| Indicator | HCA | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 61.74 | 65.39 |
| Support Level | $425.69 | $45.39 |
| Resistance Level | $512.14 | N/A |
| Average True Range (ATR) | 16.50 | 23.10 |
| MACD | 2.72 | 1.95 |
| Stochastic Oscillator | 66.37 | 94.48 |
Price Performance
Historical ComparisonAbout HCA HCA Healthcare Inc.
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the United States. As of December 2025, the firm owned and operated 190 hospitals and over 2,500 outpatient facillities across 19 states and a small foothold in the United Kingdom.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.